Quantcast
Home > Quotes > RETA

Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) Quote & Summary Data

RETA 
$72.46
*  
2.14
2.87%
Get RETA Alerts
*Delayed - data as of Aug. 23, 2019 12:30 ET  -  Find a broker to begin trading RETA now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    RETA Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 72.15 / $ 72.48
Today's High / Low
$ 75.22 / $ 71.90
Share Volume
88,579
50 Day Avg. Daily Volume
225,048
Previous Close
$ 74.60
52 Week High / Low
$ 104.53 / $ 47.50
Market Cap
2,181,505,686
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
88,579
50 Day Avg. Daily Volume:
225,048

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -4.05

Trading Range

The current last sale of $72.46 is 52.55% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 75.22 $ 104.53
 Low: $ 71.90 $ 47.50

Company Description (as filed with the SEC)

Reata's mission is to develop innovative therapies that change patients' lives for the better. We focus on developing small-molecule therapeutics with novel mechanisms of action for the treatment of severe, life-threatening diseases with few or no approved therapies. Our lead product candidates, bardoxolone methyl (Bard) and omaveloxolone (Omav), activate the transcription factor Nrf2, which plays an important role in regulating the cellular response to injury. By activating Nrf2, Bard and Omav normalize mitochondrial function, restore redox balance, and resolve inflammation. We have fully enrolled two registrational clinical trials: CARDINAL, studying Bard in chronic kidney disease (CKD) caused by Alport syndrome, and MOXIe, studying Omav in Friedreich's ataxia (FA). CKD caused by Alport syndrome and FA are rare, serious diseases with no approved therapy.  ... More ...  



Risk Grade

Where does RETA fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 74.34
Open Date:
Aug. 23, 2019
Close Price:
N/A
Close Date:
N/A


Consensus Recommendation

Analyst Info